Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 05:40PM GMT
Release Date Price: $45.69 (+1.99%)
Qian Wang
BofA Merrill Lynch, Research Division - Research Analyst

(inaudible) Today, it's my pleasure to host Ken Mills, the Chief Executive Officer from REGENXBIO, the leader in AAV-based gene therapy. Welcome.

Kenneth T. Mills
REGENXBIO Inc. - CEO, President & Director

Thanks, Qian.

Qian Wang
BofA Merrill Lynch, Research Division - Research Analyst

Looking forward to the discussion. So before we dive into more details about your program, and can you just tell us in general, how are you learning from the host base for the past few years, given the fact that you are one of the earlier adopters of AAV gene therapy in the field, in this new wave?

Kenneth T. Mills
REGENXBIO Inc. - CEO, President & Director

Yes, absolutely. Two things first. Number one, thanks to you and Ying and the team for inviting us to be here, for Bank of America, a great host, great conference. And two, I just wanted to let everyone know in the audience that today at REGENXBIO, we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot